These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 3262173

  • 21. [Anti-tumor effect of LAK (lymphokine activated killer) cells against human bladder tumors transplanted to nude mouse].
    Tsujihashi H, Ishihara H, Nakanishi A, Matsuda H, Uejima S, Akiyama T, Kurita T.
    Nihon Hinyokika Gakkai Zasshi; 1989 Feb; 80(2):204-9. PubMed ID: 2787443
    [Abstract] [Full Text] [Related]

  • 22. [Antitumor activity of human tumor infiltrating lymphocytes (TIL) and its comparison with peripheral blood lymphocytes (PBL)].
    Xu ZY.
    Zhonghua Zhong Liu Za Zhi; 1990 Sep; 12(5):345-7. PubMed ID: 2177396
    [Abstract] [Full Text] [Related]

  • 23. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors.
    Miescher S, Whiteside TL, Moretta L, von Fliedner V.
    J Immunol; 1987 Jun 01; 138(11):4004-11. PubMed ID: 3108380
    [Abstract] [Full Text] [Related]

  • 24. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
    Ohta T, Kikuchi H, Ogata H, Iwata K, Yoshida K, Katayama K, Watanabe H.
    Cancer; 1992 Aug 15; 70(4):741-8. PubMed ID: 1386555
    [Abstract] [Full Text] [Related]

  • 25. The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to autologous peripheral blood lymphocytes.
    Mizutani Y, Nio Y, Yoshida O.
    Cancer; 1992 Jun 15; 69(12):2999-3007. PubMed ID: 1591693
    [Abstract] [Full Text] [Related]

  • 26. [Augmentation of cytotoxicity of tumor infiltrating lymphocytes by interleukin-2 in gastric cancer patients].
    Gotoh K.
    Nihon Geka Gakkai Zasshi; 1985 Dec 15; 86(12):1600-7. PubMed ID: 3878935
    [Abstract] [Full Text] [Related]

  • 27. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
    Mizutani Y, Bonavida B, Nio Y, Yoshida O.
    Cancer; 1993 Feb 15; 71(4):1313-21. PubMed ID: 7679609
    [Abstract] [Full Text] [Related]

  • 28. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
    Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA.
    J Exp Med; 1983 Mar 01; 157(3):884-97. PubMed ID: 6601174
    [Abstract] [Full Text] [Related]

  • 29. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
    Itoh K, Tilden AB, Balch CM.
    Cancer Res; 1986 Jun 01; 46(6):3011-7. PubMed ID: 3486040
    [Abstract] [Full Text] [Related]

  • 30. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
    Wang YL, Si LS, Kanbour A, Herberman RB, Whiteside TL.
    Cancer Res; 1989 Nov 01; 49(21):5979-85. PubMed ID: 2507139
    [Abstract] [Full Text] [Related]

  • 31. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
    Higuchi CM, Thompson JA, Lindgren CG, Gillis S, Widmer MB, Kern DE, Fefer A.
    Cancer Res; 1989 Dec 01; 49(23):6487-92. PubMed ID: 2479463
    [Abstract] [Full Text] [Related]

  • 32. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.
    Kass R, Bellone S, Palmieri M, Canè S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD.
    Breast Cancer Res Treat; 2003 Aug 01; 80(3):275-85. PubMed ID: 14503800
    [Abstract] [Full Text] [Related]

  • 33. [Natural killer (NK) and lymphokine-activated killer (LAK) activities of a patient recovered from bladder cancer, and the characteristics of LAK cells generated from lymphocyte subsets].
    Komatsu F, Kihara K.
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Apr 01; 18(2):197-206. PubMed ID: 7553054
    [Abstract] [Full Text] [Related]

  • 34. Disease-related lymphocyte cytotoxicity in rats bearing transitional cell carcinoma of bladder. Effect of immunomodulators.
    Moroz C, Madgar I, Twig S, Lindner A, Many M.
    Int J Cancer; 1982 Jun 15; 29(6):667-72. PubMed ID: 6980847
    [Abstract] [Full Text] [Related]

  • 35. In vitro cytotoxicity and transplantation protection by autologous natural and activated killer cells against an in vitro transformed tumorigenic fibroblast line. A case study.
    Wilhelm SA, Mukherji B.
    J Clin Invest; 1985 Apr 15; 75(4):1162-8. PubMed ID: 3988936
    [Abstract] [Full Text] [Related]

  • 36. Antitumor killer lymphocytes in the peripheral blood of a patient with transitional cell carcinoma of the bladder.
    Kim CJ, Yuasa T, Kushima R, Tomoyoshi T, Seto A.
    Int J Urol; 1998 May 15; 5(3):230-6. PubMed ID: 9624553
    [Abstract] [Full Text] [Related]

  • 37. Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma.
    Kim TY, von Eschenbach AC, Filaccio MD, Hayakawa K, Parkinson DR, Balch CM, Itoh K.
    Cancer Res; 1990 Sep 01; 50(17):5263-8. PubMed ID: 2143685
    [Abstract] [Full Text] [Related]

  • 38. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
    Mizutani Y, Okada Y, Terachi T, Yoshida O.
    J Urol; 1996 Mar 01; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
    [Abstract] [Full Text] [Related]

  • 39. Keyhole limpet hemocyanine can enhance the natural killer activity of patients with transitional cell carcinoma of the bladder.
    Moltó LM, Carballido J, Jurincic C, Lapeña P, Manzano L, Salmerón I, Klippel KF, Alvarez-Mon M.
    Eur Urol; 1991 Mar 01; 19(1):74-8. PubMed ID: 2007423
    [Abstract] [Full Text] [Related]

  • 40. Antitumor activity of regional lymph node lymphocytes in patients with lung cancer.
    Yaita H, Yasumoto K, Nagashima A, Sugimachi K, Nomoto K.
    J Surg Oncol; 1988 Jul 01; 38(3):165-72. PubMed ID: 3260643
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.